Key Takeaways:
(Bloomberg) -- Waldencast plc said U.S. regulators have concluded an investigation into the company’s previous financial restatements and internal control failures, recommending no enforcement action in a major reprieve for the beauty and wellness firm.
“We are pleased with the favorable outcome of the SEC’s investigation,” Michel Brousset, Chief Executive Officer of Waldencast, said in a statement. “Throughout the Investigation, we fully cooperated and dedicated significant resources to the process.”
The inquiry by the U.S. Securities and Exchange Commission stemmed from historical accounting practices at Obagi Cosmeceuticals, which led Waldencast to restate its financial results. The company also reported material weaknesses in its internal controls over financial reporting.
Waldencast, which owns the Obagi Medical and Milk Makeup brands, voluntarily contacted the SEC to report the issues and said it incurred substantial legal and advisory costs during the probe. The conclusion of the investigation without fines or penalties removes a significant risk for investors.
The resolution allows management to focus fully on its brand-led business model, which includes the Obagi skincare line and the vegan-focused Milk Makeup brand. The removal of the regulatory uncertainty is a positive catalyst for the stock, which has been weighed down by the issue. Investors will now watch for the company's next earnings report to assess the underlying business performance without the distraction of the investigation.
This article is for informational purposes only and does not constitute investment advice.
